DE60116487D1 - 1-(pyrrolidin-1-ylmethyl)-3-(pyrrol-2-ylmethyliden)-2-indolinon derivate und deren verwendung als protein kinase inhibitoren - Google Patents
1-(pyrrolidin-1-ylmethyl)-3-(pyrrol-2-ylmethyliden)-2-indolinon derivate und deren verwendung als protein kinase inhibitorenInfo
- Publication number
- DE60116487D1 DE60116487D1 DE60116487T DE60116487T DE60116487D1 DE 60116487 D1 DE60116487 D1 DE 60116487D1 DE 60116487 T DE60116487 T DE 60116487T DE 60116487 T DE60116487 T DE 60116487T DE 60116487 D1 DE60116487 D1 DE 60116487D1
- Authority
- DE
- Germany
- Prior art keywords
- ylmethyliden
- pyrrol
- pyrrolidin
- ylmethyl
- protein kinase
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- ZHMQQCWNIPWUPV-UHFFFAOYSA-N 1-(pyrrolidin-1-ylmethyl)-3-(1h-pyrrol-2-ylmethylidene)indol-2-one Chemical class C12=CC=CC=C2C(=CC=2NC=CC=2)C(=O)N1CN1CCCC1 ZHMQQCWNIPWUPV-UHFFFAOYSA-N 0.000 title 1
- 229940045988 antineoplastic drug protein kinase inhibitors Drugs 0.000 title 1
- 239000003909 protein kinase inhibitor Substances 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/08—Vasodilators for multiple indications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/553—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having one nitrogen atom as the only ring hetero atom
- C07F9/572—Five-membered rings
- C07F9/5728—Five-membered rings condensed with carbocyclic rings or carbocyclic ring systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/6558—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system
- C07F9/65583—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system each of the hetero rings containing nitrogen as ring hetero atom
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Diabetes (AREA)
- Immunology (AREA)
- Biomedical Technology (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Hematology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Dermatology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Communicable Diseases (AREA)
- Rheumatology (AREA)
- Urology & Nephrology (AREA)
- Physical Education & Sports Medicine (AREA)
- Obesity (AREA)
- Oncology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Pain & Pain Management (AREA)
- Psychiatry (AREA)
- Endocrinology (AREA)
- Hospice & Palliative Care (AREA)
- Vascular Medicine (AREA)
- Transplantation (AREA)
- Emergency Medicine (AREA)
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US20700000P | 2000-05-24 | 2000-05-24 | |
US207000P | 2000-05-24 | ||
US22504500P | 2000-08-11 | 2000-08-11 | |
US225045P | 2000-08-11 | ||
PCT/US2001/016756 WO2001090104A2 (en) | 2000-05-24 | 2001-05-24 | -(pyrrolidin-1-ylmethyl)-3-(pyrrol-2-ylmethylidene)-2-indolinone derivatives and their use as modulators of protein kinases |
Publications (2)
Publication Number | Publication Date |
---|---|
DE60116487D1 true DE60116487D1 (de) | 2006-03-30 |
DE60116487T2 DE60116487T2 (de) | 2006-08-17 |
Family
ID=26901875
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DE60121595T Expired - Fee Related DE60121595T2 (de) | 2000-05-24 | 2001-05-24 | Mannichbaseprodrugs von 3-(pyrrol-2-ylmethylidene)-2-indolinonderivaten |
DE60116487T Expired - Fee Related DE60116487T2 (de) | 2000-05-24 | 2001-05-24 | 1-(pyrrolidin-1-ylmethyl)-3-(pyrrol-2-ylmethyliden)-2-indolinonderivate |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DE60121595T Expired - Fee Related DE60121595T2 (de) | 2000-05-24 | 2001-05-24 | Mannichbaseprodrugs von 3-(pyrrol-2-ylmethylidene)-2-indolinonderivaten |
Country Status (13)
Country | Link |
---|---|
US (8) | US6710067B2 (de) |
EP (3) | EP1294711B8 (de) |
JP (3) | JP2003534342A (de) |
AR (3) | AR041775A1 (de) |
AT (2) | ATE312093T1 (de) |
AU (3) | AU2001263399A1 (de) |
CA (3) | CA2409367A1 (de) |
DE (2) | DE60121595T2 (de) |
ES (2) | ES2253385T3 (de) |
HK (2) | HK1054552B (de) |
MY (2) | MY128449A (de) |
TW (1) | TWI270545B (de) |
WO (3) | WO2001090104A2 (de) |
Families Citing this family (66)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6051593A (en) * | 1997-06-20 | 2000-04-18 | Sugen, Inc. | 3-(cycloalkanoheteroarylidenyl)-2- indolinone protein tyrosine kinase inhibitors |
US20030153015A1 (en) * | 2000-01-20 | 2003-08-14 | Genentech, Inc. | Compositions and methods for the treatment of immune related diseases |
SK287142B6 (sk) | 2000-02-15 | 2010-01-07 | Sugen, Inc. | Inhibítory proteínkináz na báze pyrolom substituovaného 2-indolinónu, farmaceutický prípravok s ich obsahom a ich použitie |
TWI270545B (en) * | 2000-05-24 | 2007-01-11 | Sugen Inc | Mannich base prodrugs of 3-(pyrrol-2-ylmethylidene)-2-indolinone derivatives |
EP1294688A2 (de) * | 2000-06-02 | 2003-03-26 | Sugen, Inc. | Indolinon derivate als protein kinase/phosphatase inhibitoren |
AR042586A1 (es) * | 2001-02-15 | 2005-06-29 | Sugen Inc | 3-(4-amidopirrol-2-ilmetiliden)-2-indolinona como inhibidores de la protein quinasa; sus composiciones farmaceuticas; un metodo para la modulacion de la actividad catalitica de la proteinquinasa; un metodo para tratar o prevenir una afeccion relacionada con la proteinquinasa |
US6797725B2 (en) * | 2001-04-09 | 2004-09-28 | Sugen, Inc. | Prodrugs of a 3-(pyrrol-2-ylmethylidene)-2-indolinone derivatives |
AR036042A1 (es) | 2001-05-30 | 2004-08-04 | Sugen Inc | Derivados aralquilsufonil-3-(pirrol-2-ilmetiliden)-2-indolinona, sus composiciones farmaceuticas y metodo para la modulacion de la actividad catalitica de una proteina quinasa |
US6960572B2 (en) | 2001-06-21 | 2005-11-01 | Ariad Pharmaceuticals, Inc. | Indolinones and uses thereof |
CA2452392A1 (en) | 2001-06-29 | 2003-01-16 | Ab Science | Use of tyrosine kinase inhibitors for treating inflammatory bowel diseases (ibd) |
WO2003002108A2 (en) | 2001-06-29 | 2003-01-09 | Ab Science | Use of tyrosine kinase inhibitors for treating inflammatory diseases |
CA2452366A1 (en) * | 2001-06-29 | 2003-01-16 | Ab Science | Use of potent, selective and non toxic c-kit inhibitors for treating tumor angiogenesis |
US7727731B2 (en) | 2001-06-29 | 2010-06-01 | Ab Science | Potent, selective and non toxic c-kit inhibitors |
ATE388711T1 (de) * | 2001-09-20 | 2008-03-15 | Ab Science | C-kithemmer zur behandlung von bakteriellen infektionen |
EP1434774A1 (de) | 2001-10-10 | 2004-07-07 | Sugen, Inc. | 3-(4-substituierte heterocyclyl)-pyrrol-2-ylmethylidene)-2-indolinone derivate als protein-kinase-inhibitoren |
AU2002346457A1 (en) * | 2001-11-21 | 2003-06-10 | Pharmacia And Upjohn Company | Pharmaceutical formulations comprising indolinone derivatives |
US6797825B2 (en) | 2001-12-13 | 2004-09-28 | Abbott Laboratories | Protein kinase inhibitors |
US20030187026A1 (en) | 2001-12-13 | 2003-10-02 | Qun Li | Kinase inhibitors |
US7910586B2 (en) * | 2002-01-04 | 2011-03-22 | The Rockefeller University | Compositions and methods for prevention and treatment of amyloid-β peptide-related disorders |
ATE326970T1 (de) * | 2002-02-22 | 2006-06-15 | Us Gov Veterans Affairs | Verwendung von 4-(4-methylpiperazin-1-ylmethyl)-n 4-methyl-3-(4-pyridin-3-yl) pyrimidin-2-ylamino) phenyl benzamid zur behandlung von seminomen |
BR0308753A (pt) * | 2002-03-22 | 2005-01-11 | Bayer Pharmaceuticals Corp | Método para produzir pseudo-ilhotas |
US20050032871A1 (en) * | 2002-09-03 | 2005-02-10 | Sugen, Inc. | Sulfonylated pyrrole-2-indolinone derivatives as kinase inhibitors |
AR042042A1 (es) * | 2002-11-15 | 2005-06-08 | Sugen Inc | Administracion combinada de una indolinona con un agente quimioterapeutico para trastornos de proliferacion celular |
WO2004050681A2 (en) * | 2002-11-15 | 2004-06-17 | Exelixis, Inc. | Kinase modulators |
AU2003295658A1 (en) * | 2002-11-27 | 2004-06-23 | Allergan, Inc. | Indol derivatives and their use as kinase inhibitors |
US6747025B1 (en) | 2002-11-27 | 2004-06-08 | Allergan, Inc. | Kinase inhibitors for the treatment of disease |
JP4879492B2 (ja) * | 2002-11-27 | 2012-02-22 | アラーガン、インコーポレイテッド | 疾患の治療のためのキナーゼ阻害剤 |
US6699863B1 (en) | 2002-11-27 | 2004-03-02 | Allergan, Inc. | Kinase inhibitors for the treatment of disease |
HUP0500844A2 (en) * | 2002-12-09 | 2007-08-28 | Univ Texas | Methods for selectively inhibiting janus tyrosine kinase 3(jak3) |
US7452913B2 (en) * | 2003-02-24 | 2008-11-18 | Pharmacia & Upjohn Company | Polymorphs of pyrrole substituted 2-indolinone protein kinase inhibitors |
KR101102229B1 (ko) | 2003-05-27 | 2012-01-05 | 닐스 리차드 웰쉬 | 당뇨병을 치료하기 위한 티로신 키나제 억제제의 용도 |
ATE506077T1 (de) * | 2003-10-16 | 2011-05-15 | Imclone Llc | Fibroblasten-wachstumsfaktor-1-hemmer und behandlungsverfahren dafür |
US20050182122A1 (en) * | 2003-11-20 | 2005-08-18 | Bello Carlo L. | Method of treating abnormal cell growth using indolinone compounds |
US7488817B2 (en) * | 2004-02-02 | 2009-02-10 | The Trustees Of The University Of Pennsylvania | Metal complex protein kinase inhibitors |
WO2006032164A1 (fr) * | 2004-09-23 | 2006-03-30 | Beijing Molecule Science And Technology Co., Ltd. | Dérivés de 2-indolinone substituée en position 1 et 3, préparation, composition et utilisation de ceux-ci |
CN101054379A (zh) * | 2006-04-11 | 2007-10-17 | 上海恒瑞医药有限公司 | 吡咯取代的嘧啶酮衍生物、其制备方法及其在医药上的用途 |
US20100113421A1 (en) * | 2006-10-06 | 2010-05-06 | Williams Theresa M | Non-nucleoside reverse transcriptase inhibitors |
CA2681222C (en) * | 2007-03-19 | 2016-07-26 | State Of Oregon Acting By And Through The Oregon State Board Of Higher Education On Behalf Of The University Of Oregon | Mannich base n-oxide drugs |
US8642067B2 (en) | 2007-04-02 | 2014-02-04 | Allergen, Inc. | Methods and compositions for intraocular administration to treat ocular conditions |
JPWO2009123080A1 (ja) * | 2008-04-01 | 2011-07-28 | アステラス製薬株式会社 | インドリノン化合物 |
US8106039B2 (en) * | 2008-04-30 | 2012-01-31 | The Trustees Of The University Of Pennsylvania | Metal complex phosphatidyl-inositol-3-kinase inhibitors |
JP2012500837A (ja) * | 2008-08-25 | 2012-01-12 | ジェネリクス・(ユーケー)・リミテッド | 新規な結晶型およびその調製方法 |
EP2318393A1 (de) * | 2008-08-25 | 2011-05-11 | Generics [UK] Limited | Neue polymorphe von sunitinib und verfahren zu ihrer herstellung |
EP2181991A1 (de) * | 2008-10-28 | 2010-05-05 | LEK Pharmaceuticals D.D. | Neuartige Sunitinib-Salze |
EP2186809A1 (de) * | 2008-11-13 | 2010-05-19 | LEK Pharmaceuticals D.D. | Neue kristalline Form von Sunitinib-Malat |
WO2010087315A1 (ja) * | 2009-01-29 | 2010-08-05 | 株式会社林原生物化学研究所 | 抗アルツハイマー病剤 |
WO2010087306A1 (ja) * | 2009-01-29 | 2010-08-05 | 株式会社林原生物化学研究所 | 抗神経変性疾患剤 |
JPWO2010087313A1 (ja) * | 2009-01-29 | 2012-08-02 | 株式会社林原生物化学研究所 | 神経突起伸展促進剤 |
PL2445502T5 (pl) | 2009-06-25 | 2023-03-13 | Alkermes Pharma Ireland Limited | Związki heterocykliczne do leczenia zaburzeń neurologicznych i psychologicznych |
WO2010151711A1 (en) * | 2009-06-25 | 2010-12-29 | Alkermes, Inc. | Prodrugs of nh-acidic compounds |
WO2011016861A2 (en) | 2009-08-05 | 2011-02-10 | Intra-Cellular Therapies, Inc. | Novel regulatory proteins and inhibitors |
MX336071B (es) * | 2009-08-14 | 2016-01-06 | Opko Health Inc | Formulaciones intravenosas de antagonistas de neurocinina 1. |
BR112012024380A2 (pt) | 2010-03-25 | 2015-09-15 | Glaxosmithkline Llc | compostos químicos |
ES2691671T3 (es) * | 2010-06-24 | 2018-11-28 | Alkermes Pharma Ireland Limited | Profármacos de compuestos NH-acídicos: derivados de éster, carbonato, carbamato y fosfonato |
US10220020B2 (en) | 2010-12-23 | 2019-03-05 | Nektar Therapeutics | Polymer-des-ethyl sunitinib conjugates |
WO2012088529A1 (en) | 2010-12-23 | 2012-06-28 | Nektar Therapeutics | Polymer-sunitinib conjugates |
US9034867B2 (en) | 2011-03-18 | 2015-05-19 | Alkermes Pharma Ireland Limited | Pharmaceutical compositions comprising sorbitan esters |
NZ630643A (en) | 2012-03-19 | 2017-08-25 | Alkermes Pharma Ireland Ltd | Pharmaceutical compositions comprising fatty acid esters |
CA2867137C (en) | 2012-03-19 | 2020-12-08 | Alkermes Pharma Ireland Limited | Pharmaceutical compositions comprising aripiprazole prodrugs and benzyl alcohol |
JP6219918B2 (ja) | 2012-03-19 | 2017-10-25 | アルカームス ファーマ アイルランド リミテッド | グリセロールエステルを含む医薬組成物 |
US9193685B2 (en) | 2012-09-19 | 2015-11-24 | Alkermes Pharma Ireland Limited | Pharmaceutical compositions having improved storage stability |
AU2015231278B2 (en) | 2014-03-20 | 2020-01-23 | Alkermes Pharma Ireland Limited | Aripiprazole formulations having increased injection speeds |
CN104610231B (zh) * | 2015-01-28 | 2016-08-17 | 广州葳澜生物科技有限公司 | 一种舒尼替尼前药 |
JP7384812B2 (ja) | 2018-03-05 | 2023-11-21 | アルカームス ファーマ アイルランド リミテッド | アリピプラゾール投与戦略 |
EP3771711A1 (de) | 2019-07-29 | 2021-02-03 | Bayer Animal Health GmbH | Pyrazolderivate für die kontrolle von arthropoden |
CN114213396B (zh) * | 2022-01-27 | 2023-03-24 | 深圳市乐土生物医药有限公司 | 一种吲哚-2-酮类化合物及其制备方法与用途 |
Family Cites Families (73)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
NL104796C (de) | 1957-08-19 | |||
NL45080C (de) | 1935-08-22 | |||
DE683735C (de) | 1936-05-12 | 1939-11-14 | Paul Hadamovsky | Verfahren zur Kuehlung, Verfluessigung und Speicherung von Chlor und anderen aggressi Gasen |
DE878539C (de) | 1939-08-17 | 1953-06-05 | Hoechst Ag | Verfahren zur Herstellung von Methinfarbstoffen |
BE553661A (de) | 1955-12-23 | |||
BE558210A (de) | 1956-06-08 | |||
FR1398224A (fr) | 1964-05-06 | 1965-05-07 | Ici Ltd | Procédé de teinture de matières textiles de polyacrylonitrile |
FR1599772A (de) | 1968-09-17 | 1970-07-20 | ||
DE2159362A1 (de) | 1971-11-30 | 1973-06-14 | Bayer Ag | Nitrofuranderivate, verfahren zu ihrer herstellung sowie ihre verwendung als arzneimittel |
DE2159361A1 (de) | 1971-11-30 | 1973-06-14 | Bayer Ag | Nitrofuranderivate, verfahren zu ihrer herstellung sowie ihre verwendung als arzneimittel |
DE2159360A1 (de) | 1971-11-30 | 1973-06-14 | Bayer Ag | Nitrofuranderivate, verfahren zu ihrer herstellung sowie ihre verwendung als arzneimittel |
DE2159363A1 (de) | 1971-11-30 | 1973-06-14 | Bayer Ag | Antimikrobielle mittel |
GB1384599A (en) | 1972-05-04 | 1975-02-19 | Colgate Palmolive Co | Coloured detergent compositions |
US4420639C1 (en) | 1973-09-11 | 2001-08-21 | Beecham Group Ltd | Aromatic compounds |
US4002749A (en) | 1975-08-12 | 1977-01-11 | E. R. Squibb & Sons, Inc. | Substituted indolinones |
US4053613A (en) | 1975-09-17 | 1977-10-11 | E. R. Squibb & Sons, Inc. | 1,3,thiazolinyl and 1,3 thiazinyl substituted indolinones |
US5389613A (en) | 1979-09-21 | 1995-02-14 | Roussel Uclaf | Method of treating prostate adenocarcinoma, prostate benign hypertrophia and endometriosis |
FR2465486A1 (fr) | 1979-09-21 | 1981-03-27 | Roussel Uclaf | Nouvelle application utilisant la lh-rh ou des agonistes |
ATE28864T1 (de) | 1982-07-23 | 1987-08-15 | Ici Plc | Amide-derivate. |
DE3310891A1 (de) | 1983-03-25 | 1984-09-27 | Boehringer Mannheim Gmbh, 6800 Mannheim | Neue indolinon-(2)-derivate, verfahren zu ihrer herstellung, diese verbindungen enthaltende arzneimittel und zwischenprodukte |
DE3426419A1 (de) | 1984-07-18 | 1986-01-23 | Boehringer Mannheim Gmbh, 6800 Mannheim | Neue oxindol-derivate, verfahren zu ihrer herstellung, diese verbindungen enthaltende arzneimittel und zwischenprodukte |
JPS6229570A (ja) | 1985-07-29 | 1987-02-07 | Kanegafuchi Chem Ind Co Ltd | 3,5−ジイソプロピルベンジリデン複素環式化合物 |
JPS6239564A (ja) | 1985-08-13 | 1987-02-20 | Kanegafuchi Chem Ind Co Ltd | α−ベンジリデン−γ−ブチロラクトンまたはγ−ブチロラクタム誘導体 |
WO1993012786A1 (en) | 1986-07-10 | 1993-07-08 | Howard Harry R Jr | Indolinone derivatives |
JPS63141955A (ja) | 1986-12-03 | 1988-06-14 | Kanegafuchi Chem Ind Co Ltd | トリベンジルアミン誘導体 |
GB8816944D0 (en) | 1988-07-15 | 1988-08-17 | Sobio Lab | Compounds |
GB9004483D0 (en) | 1990-02-28 | 1990-04-25 | Erba Carlo Spa | New aryl-and heteroarylethenylene derivatives and process for their preparation |
CA2012634A1 (en) | 1990-03-20 | 1991-09-20 | Hassan Salari | Tyrphostins for treatment of allergic, inflammatory and cardiovascular diseases |
US5196446A (en) | 1990-04-16 | 1993-03-23 | Yissum Research Development Company Of The Hebrew University Of Jerusalem | Certain indole compounds which inhibit EGF receptor tyrosine kinase |
US5302606A (en) | 1990-04-16 | 1994-04-12 | Rhone-Poulenc Rorer Pharmaceuticals Inc. | Styryl-substituted pyridyl compounds which inhibit EGF receptor tyrosine kinase |
WO1992007830A2 (en) | 1990-10-29 | 1992-05-14 | Pfizer Inc. | Oxindole peptide antagonists |
AU658646B2 (en) | 1991-05-10 | 1995-04-27 | Rhone-Poulenc Rorer International (Holdings) Inc. | Bis mono-and bicyclic aryl and heteroaryl compounds which inhibit EGF and/or PDGF receptor tyrosine kinase |
GB9115160D0 (en) | 1991-07-12 | 1991-08-28 | Erba Carlo Spa | Methylen-oxindole derivatives and process for their preparation |
US5124347A (en) | 1991-07-31 | 1992-06-23 | Warner-Lambert Co. | 3-5-ditertiarybutylphenyl-4-hydroxymethylidene derivatives of 1,3-dihydro-2H-indole-2-ones as antiinflammatory agents |
JPH0558894A (ja) | 1991-08-27 | 1993-03-09 | Kanegafuchi Chem Ind Co Ltd | 抗腫瘍剤 |
US5322950A (en) | 1991-12-05 | 1994-06-21 | Warner-Lambert Company | Imidazole with angiotensin II antagonist properties |
US5389661A (en) | 1991-12-05 | 1995-02-14 | Warner-Lambert Company | Imidazole and 1,2,4-triazole derivatives with angiotensin II antagonist properties |
US5994362A (en) | 1992-03-11 | 1999-11-30 | Merck & Co., Inc. | Method of treatment for prostatic cancer |
FR2689397A1 (fr) | 1992-04-01 | 1993-10-08 | Adir | Utilisation des dérivés de la 3-(3,5-Ditert-Butyl-4-Hydroxybenzylidenyl) Indoline-2-one pour l'obtention de médicaments. |
FR2694004B1 (fr) | 1992-07-21 | 1994-08-26 | Adir | Nouvelles 3-(Hydroxybenzylidényl)-indoline-2-ones et 3-(hydroxybenzylidényl)-indoline-2-thiones, leurs procédés de préparation, et les compositions pharmaceutiques qui les contiennent. |
KR950704291A (ko) | 1992-10-21 | 1995-11-17 | 알렌 제이. 스피겔 | 거울상 이성질체 시스-3-(4,6-디하이드록시크로만-3-일메틸)벤조산(enantiomeric cis-3-(4,6-dihydroxychroman-3-ylmethyl)benzoic acids) |
GB9226855D0 (en) | 1992-12-23 | 1993-02-17 | Erba Carlo Spa | Vinylene-azaindole derivatives and process for their preparation |
DE59402281D1 (de) | 1993-06-28 | 1997-05-07 | Bayer Ag | Massefärben von Kunststoffen |
GB9313638D0 (en) | 1993-07-01 | 1993-08-18 | Erba Carlo Spa | Arylidene and heteroarylidene oxindole derivatives and process for their preparation |
GB9326136D0 (en) | 1993-12-22 | 1994-02-23 | Erba Carlo Spa | Biologically active 3-substituted oxindole derivatives useful as anti-angiogenic agents |
CA2181358A1 (en) | 1994-01-21 | 1995-07-27 | Nancy M. Gray | Methods and compositions for treating androgen-dependent diseases using optically pure r-(-)-casodex |
GB9412719D0 (en) | 1994-06-24 | 1994-08-17 | Erba Carlo Spa | Substituted azaindolylidene compounds and process for their preparation |
GB9423997D0 (en) | 1994-11-28 | 1995-01-11 | Erba Carlo Spa | Substituted 3-arylidene-7-azaoxindole compounds and process for their preparation |
GB9501567D0 (en) | 1995-01-26 | 1995-03-15 | Pharmacia Spa | Hydrosoluble 3-arylidene-2-oxindole derivatives as tyrosine kinase inhibitors |
GB9507298D0 (en) | 1995-04-07 | 1995-05-31 | Pharmacia Spa | Substituted indolylmethylene-oxindale analogues as tyrosine kinase inhibitors |
US5880141A (en) | 1995-06-07 | 1999-03-09 | Sugen, Inc. | Benzylidene-Z-indoline compounds for the treatment of disease |
US5777134A (en) | 1995-10-26 | 1998-07-07 | Merck & Co., Inc. | 4-oxa and 4-thia steriods |
RU2145852C1 (ru) | 1996-01-17 | 2000-02-27 | Тайхо Фармасьютикал Ко., Лтд | Ингибитор гипертрофии интимы, применение оксиндолового производного для получения ингибитора гипертрофии интимы, композиция для ингибирования гипертрофии интимы, способ предупреждения и лечения гипертрофии интимы |
EP0788890A1 (de) | 1996-02-06 | 1997-08-13 | Agfa-Gevaert N.V. | Farbstoffe und Farbstoffdonorelemente zur thermischen Farbstoffübertragungsaufzeichnung |
ATE308520T1 (de) | 1996-08-23 | 2005-11-15 | Sugen Inc | Kombinatorische bibliotheken von indolinone und verwandte produkte und verfahren zur behandlung von krankheiten |
WO1998024432A2 (en) | 1996-12-05 | 1998-06-11 | Sugen, Inc. | Use of indolinone compounds as modulators of protein kinases |
EP1014953B1 (de) | 1997-03-05 | 2012-04-25 | Sugen, Inc. | Hydrophobe pharmazeutische wirkstoffe enthaltende zubereitungen |
EP0984930B1 (de) | 1997-05-07 | 2005-04-06 | Sugen, Inc. | 2-indolinonderivate als modulatoren der proteinkinase-ativität |
AU7723198A (en) | 1997-06-04 | 1998-12-21 | University Of Tennessee Research Corporation, The | Non-steroidal radiolabeled agonist/antagonist compounds and their use in prostate cancer imaging |
GB9716557D0 (en) | 1997-08-06 | 1997-10-08 | Glaxo Group Ltd | Benzylidene-1,3-dihydro-indol-2-one derivatives having anti-cancer activity |
US6133305A (en) | 1997-09-26 | 2000-10-17 | Sugen, Inc. | 3-(substituted)-2-indolinones compounds and use thereof as inhibitors of protein kinase activity |
DE19816624A1 (de) | 1998-04-15 | 1999-10-21 | Boehringer Ingelheim Pharma | Neue substituierte Indolinone, ihre Herstellung und ihre Verwendung als Arzneimittel |
CO5031249A1 (es) * | 1998-05-29 | 2001-04-27 | Sugen Inc | Pirrol substituido-2-indolinonas inhibidoras de proteinci-nasas |
DE19826940A1 (de) | 1998-06-17 | 1999-12-23 | Bayer Ag | Substituierte N-Aryl-O-alkyl-carbamate |
CA2383623A1 (en) | 1998-08-04 | 2000-02-17 | Sugen, Inc. | 3-methylidenyl-2-indolinone modulators of protein kinase |
CA2354510A1 (en) | 1998-12-17 | 2000-06-22 | F. Hoffmann-La Roche Ag | 4- and 5-alkynyloxindoles and 4- and 5-alkenyloxindoles |
KR20010101266A (ko) | 1998-12-17 | 2001-11-14 | 프리돌린 클라우스너, 롤란드 비. 보레르 | Jnk 단백질 키나제의 억제제로서의 4-아릴옥신돌 |
CN1138773C (zh) | 1998-12-17 | 2004-02-18 | 霍夫曼-拉罗奇有限公司 | 4-链烯基(和炔基)氧吲哚作为细胞周期蛋白-依赖性激酶尤其是cdk2的抑制剂 |
MXPA01006742A (es) | 1998-12-31 | 2004-04-21 | Sugen Inc | Compuestos 3-heteroarilidenil-2-indolinona para modular la actividad de la quinasa de proteina y para utilizarse en la quimioterapia de cancer. |
EP1165513A1 (de) | 1999-03-24 | 2002-01-02 | Sugen, Inc. | Indolinon derivate als kinase inhibitoren |
SK287142B6 (sk) | 2000-02-15 | 2010-01-07 | Sugen, Inc. | Inhibítory proteínkináz na báze pyrolom substituovaného 2-indolinónu, farmaceutický prípravok s ich obsahom a ich použitie |
TWI270545B (en) | 2000-05-24 | 2007-01-11 | Sugen Inc | Mannich base prodrugs of 3-(pyrrol-2-ylmethylidene)-2-indolinone derivatives |
AU6821301A (en) * | 2000-06-07 | 2001-12-17 | Ortho Mcneil Pharm Inc | Method to detect modulators of vegf kinase domain |
-
2001
- 2001-05-23 TW TW090112409A patent/TWI270545B/zh not_active IP Right Cessation
- 2001-05-23 MY MYPI20012452A patent/MY128449A/en unknown
- 2001-05-23 MY MYPI20012435A patent/MY128450A/en unknown
- 2001-05-24 AT AT01937687T patent/ATE312093T1/de not_active IP Right Cessation
- 2001-05-24 US US09/863,804 patent/US6710067B2/en not_active Expired - Fee Related
- 2001-05-24 CA CA002409367A patent/CA2409367A1/en not_active Abandoned
- 2001-05-24 AR ARP010102489A patent/AR041775A1/es unknown
- 2001-05-24 JP JP2001586291A patent/JP2003534342A/ja active Pending
- 2001-05-24 AU AU2001263399A patent/AU2001263399A1/en not_active Abandoned
- 2001-05-24 ES ES01937687T patent/ES2253385T3/es not_active Expired - Lifetime
- 2001-05-24 DE DE60121595T patent/DE60121595T2/de not_active Expired - Fee Related
- 2001-05-24 AT AT01939357T patent/ATE333453T1/de not_active IP Right Cessation
- 2001-05-24 AU AU2001264885A patent/AU2001264885A1/en not_active Abandoned
- 2001-05-24 WO PCT/US2001/016756 patent/WO2001090104A2/en active IP Right Grant
- 2001-05-24 DE DE60116487T patent/DE60116487T2/de not_active Expired - Fee Related
- 2001-05-24 US US09/863,819 patent/US6482848B2/en not_active Expired - Fee Related
- 2001-05-24 AR ARP010102488A patent/AR042383A1/es unknown
- 2001-05-24 WO PCT/US2001/016757 patent/WO2001090068A2/en active IP Right Grant
- 2001-05-24 EP EP01937687A patent/EP1294711B8/de not_active Expired - Lifetime
- 2001-05-24 AU AU2001264877A patent/AU2001264877A1/en not_active Abandoned
- 2001-05-24 CA CA002408709A patent/CA2408709A1/en not_active Abandoned
- 2001-05-24 JP JP2001586290A patent/JP2003534341A/ja not_active Withdrawn
- 2001-05-24 EP EP01939357A patent/EP1301507B1/de not_active Expired - Lifetime
- 2001-05-24 JP JP2001586257A patent/JP2003534323A/ja not_active Withdrawn
- 2001-05-24 US US09/863,905 patent/US6451838B1/en not_active Expired - Fee Related
- 2001-05-24 EP EP01939349A patent/EP1283835A2/de not_active Ceased
- 2001-05-24 CA CA002409430A patent/CA2409430A1/en not_active Abandoned
- 2001-05-24 AR ARP010102490A patent/AR033977A1/es unknown
- 2001-05-24 WO PCT/US2001/016741 patent/WO2001090103A2/en not_active Application Discontinuation
- 2001-05-24 ES ES01939357T patent/ES2269416T3/es not_active Expired - Lifetime
-
2002
- 2002-09-16 US US10/243,942 patent/US6716870B2/en not_active Expired - Fee Related
- 2002-09-16 US US10/243,663 patent/US20030045565A1/en not_active Abandoned
-
2003
- 2003-05-05 US US10/429,895 patent/US7008943B2/en not_active Expired - Fee Related
- 2003-09-22 HK HK03106800.4A patent/HK1054552B/zh not_active IP Right Cessation
- 2003-09-24 HK HK03106876A patent/HK1054741A1/xx not_active IP Right Cessation
- 2003-12-24 US US10/743,909 patent/US7053113B2/en not_active Expired - Fee Related
-
2004
- 2004-02-10 US US10/774,415 patent/US7112603B2/en not_active Expired - Fee Related
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
DE60116487D1 (de) | 1-(pyrrolidin-1-ylmethyl)-3-(pyrrol-2-ylmethyliden)-2-indolinon derivate und deren verwendung als protein kinase inhibitoren | |
DE60325761D1 (de) | Diaminotriazole derivate und deren verwendung als protein kinase inhibitoren | |
ATE430754T1 (de) | Phosphororganische indazolderivate und deren verwendung als proteinkinaseinhibitoren | |
EE200300385A (et) | 3-(4-amidopürrool-2-üülmetülideen)-2-indolinooni derivaadid kui proteiini kinaasi inhibiitorid | |
ATE367381T1 (de) | Neue spirotricyclische derivate und deren verwendung als phosphodiesterase-7-inhibitoren | |
ATE445613T1 (de) | Indolylmaleimidderivative als proteinkinase-c- inhibitoren | |
ATE394102T1 (de) | Substituierte chinazolin-derivate und deren verwendung als aurora-2-kinase inhibitoren | |
ATE299881T1 (de) | 4-substituierte 7-aza-indolin-2-one und ihre anwendung als protein kinase inhibitoren | |
DE60030574D1 (de) | Fünfgliedrige derivate von heterozyklen und ihre verwendung als monoaminoxidase-inhibitoren | |
DE60113719D1 (de) | Chinuclidincarbamat derivate und deren verwendung als m3 antagonisten | |
DE69833223D1 (de) | 4-aminothiazol derivate, deren herstellung und deren verwendung als inhibitoren cyclin-abhängiger kinasen | |
DE60208661D1 (de) | Diaminothiazole und ihre verwendung als cyclinabhängige kinase inhibitoren | |
EE200300085A (et) | Pürasooli derivaadid ja nende kasutamine proteiini kinaasi inhibiitoritena | |
DE59908600D1 (de) | Substituierte benzimidazole und ihre verwendung als parp inhibitoren | |
DE50015651D1 (de) | Cycloalkylsubstituierte benzimidazole und ihre verwendung als parp inhibitoren | |
DE50311397D1 (de) | Heterocyclisch substituierte indolinone und deren verwendung als rezeptor-tyrosinkinasen inhibitoren | |
ATE316527T1 (de) | Substituierte indolinone als tyrosinkinase inhibitoren | |
ATE282593T1 (de) | Indolin-2-on derivate und deren verwendung als liganden der ocytocin rezeptoren | |
DE69711020D1 (de) | Thiazole derivate als protein kinase c inhibitoren | |
DE50105955D1 (de) | Indol-3-yl-derivate und deren verwendung als integrin-inhibitoren | |
ATE551329T1 (de) | Chinazolinonderivate und deren verwendung als cb- agonisten | |
ATE520399T1 (de) | Aminoindazole derivate als kinase inhibitoren | |
ATE283852T1 (de) | Naphthostyril derivate und deren verwendung als inhibitoren von cyclin-abhängigen kinasen | |
NO20031698D0 (no) | Krystallformer av 1-(6-klor-5-(trifluormetyl)-2- pyridinyl)piperazin-hydroklorid | |
DE60322642D1 (de) | Imidazolderivate und deren Verwendung als peripheral-selektive Inhibitoren von Dopamin-beta-Hydroxylasen |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
8364 | No opposition during term of opposition | ||
8339 | Ceased/non-payment of the annual fee |